Inclusion criteria | Exclusion criteria |
---|---|
Age ≥ 1 to < 19 years | Planned urological surgery expected to influence renal function |
Prior participation in FIONA study | Patients who are candidates for renal transplantation |
CKD stages 1–3 (eGFR ≥ 30 mL/min/1.73 m2) for children aged ≥ 1 year to < 19 years at FIONA EoT and visit 1 | Systemic hypertension (stage 2 as defined by the institutional guidelines on BP management |
On a maximum tolerated dose of RAASi | Systemic hypotension defined as symptomatic hypotension or a mean systolic BP below the 5th percentile for age, sex, and height but no lower than 80 mmHg for participants < 18 years and symptomatic hypotension or a mean SBP < 90 mmHg in participants ≥ 18 years at visit 1 |
Serum K+  ≤ 5.0 mmol/L for children ≥ 2 years old and ≤ 5.3 mmol/L for children < 2 years old at both FIONA EoT and visit 1 | Concomitant therapy with an MRA, any renin inhibitor, any SGLT2i, ARNI or potassium-sparing diuretic |
 | Concomitant therapy with both ACEi and ARBs together |
 | Concomitant therapy with strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers |